Financial ConstraintsInsufficient capital to materially advance into Phase 2 studies for both Probudur and Envelta.
Leadership InstabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
Regulatory ComplianceVirpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until a specific date to regain compliance.